Evaluation of a novel biomarker as a predictor of response, stratification tool, and measure of pharmacology for a disease modifying osteoarthritis therapeutic
Lead Participant:
GLAXOSMITHKLINE PLC
Abstract
Period 8 claim submitted
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| GLAXOSMITHKLINE PLC | £817,158 | £ 227,415 |
Participant |
||
| UNIVERSITY OF OXFORD | £354,683 | £ 354,683 |
People |
ORCID iD |